Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 913215223 | 9132152 | 23 | F | 2012 | 20160714 | 20130301 | 20160729 | EXP | DE-FRI-1000043006 | FOREST | 0.00 | M | Y | 0.00000 | 20160729 | OT | DK | DE |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 913215223 | 9132152 | 1 | PS | ESCITALOPRAM | ESCITALOPRAM OXALATE | 1 | Oral | 2.5 - 10 MG PER DAY; FOR SIX MONTHS 10 MG/DAY | Y | 21365 | ORAL DROPS | ||||||||
| 913215223 | 9132152 | 2 | SS | ESCITALOPRAM | ESCITALOPRAM OXALATE | 1 | Y | 21365 | |||||||||||
| 913215223 | 9132152 | 3 | SS | ESCITALOPRAM | ESCITALOPRAM OXALATE | 1 | Y | 21365 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 913215223 | 9132152 | 1 | Depression |
| 913215223 | 9132152 | 2 | Somatic symptom disorder |
| 913215223 | 9132152 | 3 | Pain |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 913215223 | 9132152 | HO |
| 913215223 | 9132152 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 913215223 | 9132152 | Alopecia | |
| 913215223 | 9132152 | Arrhythmia | |
| 913215223 | 9132152 | Asthenia | |
| 913215223 | 9132152 | Atrial fibrillation | |
| 913215223 | 9132152 | Blood testosterone decreased | |
| 913215223 | 9132152 | Coronary artery disease | |
| 913215223 | 9132152 | Depressed level of consciousness | |
| 913215223 | 9132152 | Diabetes mellitus | |
| 913215223 | 9132152 | Diffuse alopecia | |
| 913215223 | 9132152 | Disturbance in attention | |
| 913215223 | 9132152 | Dyslipidaemia | |
| 913215223 | 9132152 | Glycosylated haemoglobin increased | |
| 913215223 | 9132152 | Hormone level abnormal | |
| 913215223 | 9132152 | Hyperhidrosis | |
| 913215223 | 9132152 | Lipid metabolism disorder | |
| 913215223 | 9132152 | Lipoprotein (a) increased | |
| 913215223 | 9132152 | Migraine | |
| 913215223 | 9132152 | Mood swings | |
| 913215223 | 9132152 | Obesity | |
| 913215223 | 9132152 | Restlessness | |
| 913215223 | 9132152 | Seborrhoeic dermatitis | |
| 913215223 | 9132152 | Supraventricular extrasystoles | |
| 913215223 | 9132152 | Ventricular extrasystoles | |
| 913215223 | 9132152 | Weight increased |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 913215223 | 9132152 | 1 | 201004 | 201207 | 0 |